VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
Kemas kini terakhir: 2 jam lalu459.62
2.59 (0.57%)
Penutupan Terdahulu | 457.03 |
Buka | 458.45 |
Jumlah Dagangan | 763,957 |
Purata Dagangan (3B) | 1,679,734 |
Modal Pasaran | 118,029,033,472 |
Harga / Pendapatan (P/E Ke hadapan) | 25.71 |
Harga / Jualan (P/S) | 10.67 |
Harga / Buku (P/B) | 7.15 |
Julat 52 Minggu | |
Tarikh Pendapatan | 7 Aug 2025 |
Margin Keuntungan | -8.91% |
Margin Operasi (TTM) | 37.22% |
EPS Cair (TTM) | -3.81 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
Nisbah Semasa (MRQ) | 2.65 |
Aliran Tunai Operasi (OCF TTM) | -980.30 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
Pulangan Atas Aset (ROA TTM) | 11.77% |
Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Vertex Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 1.38 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Large Value |
% Dimiliki oleh Orang Dalam | 0.15% |
% Dimiliki oleh Institusi | 97.64% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Capital World Investors | 31 Mar 2025 | 28,533,308 |
Jpmorgan Chase & Co | 31 Mar 2025 | 7,755,645 |
Jennison Associates Llc | 31 Mar 2025 | 5,062,442 |
Alliancebernstein L.P. | 31 Mar 2025 | 3,953,512 |
Loomis Sayles & Co L P | 31 Mar 2025 | 3,748,331 |
Morgan Stanley | 31 Mar 2025 | 3,408,520 |
Amundi | 31 Mar 2025 | 3,098,869 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 550.00 (HC Wainwright & Co., 19.66%) | Beli |
Median | 503.00 (9.44%) | |
Rendah | 420.00 (RBC Capital, -8.62%) | Pegang |
Purata | 489.29 (6.46%) | |
Jumlah | 3 Beli, 4 Pegang | |
Harga Purata @ Panggilan | 446.65 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 23 Jun 2025 | 550.00 (19.66%) | Beli | 443.54 |
Morgan Stanley | 20 Jun 2025 | 460.00 (0.08%) | Pegang | 440.87 |
06 May 2025 | 464.00 (0.95%) | Pegang | 450.03 | |
RBC Capital | 17 Jun 2025 | 420.00 (-8.62%) | Pegang | 441.99 |
06 May 2025 | 423.00 (-7.97%) | Pegang | 450.03 | |
Cantor Fitzgerald | 06 May 2025 | 535.00 (16.40%) | Beli | 450.03 |
22 Apr 2025 | 535.00 (16.40%) | Beli | 490.47 | |
JP Morgan | 06 May 2025 | 515.00 (12.05%) | Beli | 450.03 |
Leerink Partners | 06 May 2025 | 503.00 (9.44%) | Pegang | 450.03 |
Scotiabank | 06 May 2025 | 442.00 (-3.83%) | Pegang | 450.03 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |